This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Illumina (ILMN) and Protara Therapeutics (TARA)

Tipranks - Tipranks - Thu Jul 2, 10:14AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT), Illumina (ILMN) and Protara Therapeutics (TARA).

4th of July Sale - 70% Off

Sarepta Therapeutics (SRPT)

In a report released yesterday, Michael Ulz from Morgan Stanley maintained a Hold rating on Sarepta Therapeutics, with a price target of $25.00. The company’s shares closed last Wednesday at $18.01.

According to TipRanks.com, Ulz is a 4-star analyst with an average return of 3.8% and a 47.3% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Aardvark Therapeutics, Inc., Kyverna Therapeutics, Inc., and Arrowhead Pharmaceuticals. ;'>

Currently, the analyst consensus on Sarepta Therapeutics is a Hold with an average price target of $23.17, implying a 27.1% upside from current levels. In a report issued on June 18, RBC Capital also maintained a Hold rating on the stock with a $19.00 price target.

See today’s best-performing stocks on TipRanks >>

Illumina (ILMN)

In a report released today, Tycho Peterson from Jefferies maintained a Hold rating on Illumina, with a price target of $150.00. The company’s shares closed last Wednesday at $181.88.

According to TipRanks.com, Peterson is a 4-star analyst with an average return of 8.9% and a 55.8% success rate. Peterson covers the Healthcare sector, focusing on stocks such as Caris Life Sciences, Inc., Tempus AI, Inc. Class A, and Bio-Rad Laboratories. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Illumina with a $155.36 average price target, implying a -11.6% downside from current levels. In a report issued on June 25, Bernstein also initiated coverage with a Hold rating on the stock with a $185.00 price target.

Protara Therapeutics (TARA)

In a report released yesterday, Brian Cheng from J.P. Morgan maintained a Buy rating on Protara Therapeutics. The company’s shares closed last Wednesday at $3.78.

According to TipRanks.com, Cheng is a 5-star analyst with an average return of 13.6% and a 56.3% success rate. Cheng covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Kyverna Therapeutics, Inc., and Odyssey Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Protara Therapeutics with a $26.00 average price target.

Read More on SRPT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).